

Ernst Lengyel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1736472/ernst-lengyel-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

145
papers

16,106
citations

55
h-index

126
g-index

182
ext. papers

18,907
ext. citations

8.6
avg. IF

6.67
L-index

#	Paper	IF	Citations
145	Resilience in the Face of Pandemic: The Impact of COVID-19 on the Psychologic Morbidity and Health-Related Quality of Life Among Women With Ovarian Cancer.. <i>JCO Oncology Practice</i> , 2022 , OP2100514 ⁰	2.3	14 ⁰
144	High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas.. <i>Gynecologic Oncology Reports</i> , 2022 , 41, 100987	1.3	0
143	Neoadjuvant chemotherapy induces genomic and transcriptomic changes in ovarian cancer. <i>Cancer Research</i> , 2021 ,	10.1	1
142	Resilience: a mediator of the negative effects of pandemic-related stress on women's mental health in the USA. <i>Archives of Women's Mental Health</i> , 2021 ,	5	4
141	Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. <i>Obstetrics and Gynecology</i> , 2021 , 137, 108-121	4.9	25
140	Healthy food for trainees: a call to action. <i>Postgraduate Medical Journal</i> , 2021 , 97, 740-741	2	
139	Change in Health-Related Socioeconomic Risk Factors and Mental Health During the Early Phase of the COVID-19 Pandemic: A National Survey of U.S. Women. <i>Journal of Women's Health</i> , 2021 , 30, 502-513 ³		9
138	The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer. <i>Cancer Research</i> , 2021 , 81, 3985-4000	10.1	4
137	The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment. <i>Cancers</i> , 2021 , 13,	6.6	1
136	Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. <i>Cell</i> , 2021 , 184, 3163-3173 ²¹	36.21	21
135	Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas. <i>Gynecologic Oncology</i> , 2021 , 163, 130-133	4.9	1
134	Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?. <i>JAMA Network Open</i> , 2020 , 3, e2014184	10.4	4
133	A streamlined mass spectrometry-based proteomics workflow for large-scale FFPE tissue analysis. <i>Journal of Pathology</i> , 2020 , 251, 100-112	9.4	50
132	Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance. <i>Cancer Research</i> , 2020 , 80, 1748-1761	10.1	44
131	Deconstructing tumor heterogeneity: the stromal perspective. <i>Oncotarget</i> , 2020 , 11, 3621-3632	3.3	12
130	Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 52-62	6.1	12
129	SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2019 , 17, 870-881	6.6	32

128	Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. <i>Nature</i> , 2019 , 569, 723-728	50.4	155
127	Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. <i>Scientific Reports</i> , 2019 , 9, 5195	4.9	10
126	New Roles for Glycogen in Tumor Progression. <i>Trends in Cancer</i> , 2019 , 5, 396-399	12.5	22
125	Ultrasensitive, multiplexed chemoproteomic profiling with soluble activity-dependent proximity ligation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 21493-21500	11.5	10
124	Metabolic reprogramming of the stromal epigenome in ovarian cancer metastasis. <i>FASEB Journal</i> , 2019 , 33, lb240	0.9	
123	Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis. <i>Gynecologic Oncology</i> , 2019 , 153, 405-415	4.9	15
122	Mesothelial Cell HIF1 α Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. <i>Cell Reports</i> , 2019 , 29, 4086-4098.e6	10.6	12
121	RADAR: differential analysis of MeRIP-seq data with a random effect model. <i>Genome Biology</i> , 2019 , 20, 294	18.3	16
120	Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. <i>Communications Biology</i> , 2019 , 2, 386	6.7	54
119	Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. <i>Cell Metabolism</i> , 2019 , 29, 141-155.e9	24.6	117
118	Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. <i>Journal of Experimental Medicine</i> , 2019 , 216, 176-194	16.6	146
117	The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer. <i>Gynecologic Oncology</i> , 2019 , 152, 228-234	4.9	14
116	A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns. <i>Biomaterials</i> , 2019 , 190-191, 63-75	15.6	25
115	Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors. <i>Trends in Cancer</i> , 2018 , 4, 374-384	12.5	168
114	Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. <i>Oncogene</i> , 2018 , 37, 2285-2301	9.2	197
113	Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 5357-5367	12.9	45
112	mA mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. <i>Nature Cell Biology</i> , 2018 , 20, 1074-1083	23.4	358
111	Who are the long-term survivors of high grade serous ovarian cancer?. <i>Gynecologic Oncology</i> , 2018 , 148, 204-212	4.9	54

110	Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. <i>Cell</i> , 2018 , 175, 159-170.e16	56.2	67
109	The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis. <i>Trends in Cancer</i> , 2018 , 4, 517-519	12.5	14
108	Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. <i>Cancer Research</i> , 2017 , 77, 1684-1696	10.1	7
107	Unsaturated Fatty Acids Maintain Cancer Cell Stemness. <i>Cell Stem Cell</i> , 2017 , 20, 291-292	18	31
106	High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. <i>Gynecologic Oncology</i> , 2017 , 146, 153-160	4.9	18
105	A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth. <i>SLAS Discovery</i> , 2017 , 22, 494-506	3.4	20
104	Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. <i>Cancer Prevention Research</i> , 2017 , 10, 255-266	3.2	15
103	An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells. <i>Nature Communications</i> , 2017 , 8, 1775	17.4	24
102	Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells. <i>Molecular Cancer Research</i> , 2017 , 15, 78-92	6.6	132
101	Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. <i>Cancer Discovery</i> , 2016 , 6, 1342-1351	24.4	116
100	Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. <i>Cell Metabolism</i> , 2016 , 24, 728-739	24.6	152
99	Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2282-2293	6.1	46
98	Patterns and utility of routine surveillance in high grade endometrial cancer. <i>Gynecologic Oncology</i> , 2015 , 137, 485-9	4.9	23
97	Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. <i>American Journal of Obstetrics and Gynecology</i> , 2015 , 212, 479.e1-479.e10	6.4	78
96	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015 , 15, 668-79	31.3	581
95	Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity. <i>Journal of Visualized Experiments</i> , 2015 , e53541	1.6	7
94	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , 2015 , 521, 489-94	50.4	890
93	Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2015 , 138, 656-62	4.9	43

92	Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. <i>Clinical Cancer Research</i> , 2015 , 21, 680-6	12.9	69
91	Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. <i>Nature Communications</i> , 2015 , 6, 6220	17.4	118
90	The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. <i>Oncotarget</i> , 2015 , 6, 11342-56	3.3	59
89	Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. <i>Oncotarget</i> , 2015 , 6, 23548-60	3.3	29
88	Three-dimensional modeling of ovarian cancer. <i>Advanced Drug Delivery Reviews</i> , 2014 , 79-80, 184-92	18.5	31
87	Old drug, new trick: repurposing metformin for gynecologic cancers?. <i>Gynecologic Oncology</i> , 2014 , 135, 614-21	4.9	55
86	Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. <i>PLoS ONE</i> , 2014 , 9, e104521	3.7	35
85	Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. <i>American Journal of Pathology</i> , 2014 , 184, 271-81	5.8	45
84	Epithelial ovarian cancer experimental models. <i>Oncogene</i> , 2014 , 33, 3619-33	9.2	140
83	Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. <i>Journal of Clinical Investigation</i> , 2014 , 124, 4614-28	15.9	189
82	miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin β expression. <i>American Journal of Pathology</i> , 2013 , 182, 1876-89	5.8	74
81	Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma. <i>Gynecologic Oncology</i> , 2013 , 129, 120-3	4.9	10
80	Adipose tissue and adipocytes support tumorigenesis and metastasis. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2013 , 1831, 1533-41	5	427
79	Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2628-39	6.1	29
78	The effects of 17 β -estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. <i>Gynecologic Oncology</i> , 2012 , 124, 134-41	4.9	9
77	Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. <i>International Journal of Cancer</i> , 2012 , 130, 1787-97	7.5	115
76	MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. <i>Cancer Discovery</i> , 2012 , 2, 1100-8	24.4	254
75	Utility of routine surveillance methods in detecting recurrence in high grade endometrial cancer patients. <i>Gynecologic Oncology</i> , 2012 , 127, S5-S6	4.9	3

74	Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. <i>Gynecologic Oncology</i> , 2012 , 127, 316-20	4.9	16
73	HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. <i>Journal of Clinical Investigation</i> , 2012 , 122, 3603-17	15.9	89
72	Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. <i>Obstetrics and Gynecology</i> , 2012 , 119, 61-7	4.9	129
71	Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. <i>Nature Medicine</i> , 2011 , 17, 1498-503	50.5	1295
70	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011 , 11, 719-25	31.3	893
69	Ligand-independent activation of c-Met by fibronectin and $\alpha_5\beta_1$ -integrin regulates ovarian cancer invasion and metastasis. <i>Oncogene</i> , 2011 , 30, 1566-76	9.2	193
68	The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2011 , 121, 218-23	4.9	8
67	A phase II, single-arm study of the anti- $\alpha_5\beta_1$ integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2011 , 121, 273-9	4.9	119
66	FOXL2 and SOX9 distinguish the lineage of the sex cord-stromal cells in gonadoblastomas. <i>Pediatric and Developmental Pathology</i> , 2011 , 14, 391-5	2.2	24
65	Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. <i>Clinical Cancer Research</i> , 2011 , 17, 459-71	12.9	61
64	The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer. <i>Cancer Discovery</i> , 2011 , 1, 100-2	24.4	53
63	Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. <i>Clinical Cancer Research</i> , 2011 , 17, 4042-51	12.9	87
62	CD95 promotes tumour growth. <i>Nature</i> , 2010 , 465, 492-6	50.4	286
61	The Müllerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial-stromal interactions. <i>Molecular and Cellular Endocrinology</i> , 2010 , 317, 112-9	4.4	17
60	The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. <i>Fertility and Sterility</i> , 2010 , 94, 1212-1217	4.8	32
59	Ovarian cancer development and metastasis. <i>American Journal of Pathology</i> , 2010 , 177, 1053-64	5.8	1010
58	An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. <i>Neoplasia</i> , 2010 , 12, 1-10	6.4	58
57	Rac1 and Rho contribute to the migratory and invasive phenotype associated with somatic E-cadherin mutation. <i>Human Molecular Genetics</i> , 2009 , 18, 3632-44	5.6	17

56	MMP-2 functions as an early response protein in ovarian cancer metastasis. <i>Cell Cycle</i> , 2009 , 8, 683-8	4.7	95
55	Up-regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of extravillous trophoblast cells during early implantation. <i>Endocrinology</i> , 2009 , 150, 4306-15	4.8	41
54	Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. <i>Cancer Prevention Research</i> , 2009 , 2, 792-9	3.2	12
53	Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. <i>Cancer Treatment and Research</i> , 2009 , 149, 335-51	3.5	66
52	{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. <i>American Journal of Pathology</i> , 2009 , 175, 2184-96	5.8	57
51	A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2009 , 17, 57-67	1.9	34
50	Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. <i>Gynecologic Oncology</i> , 2008 , 111, 537-9	4.9	13
49	Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2008 , 111, 173-8	4.9	39
48	The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. <i>Genes and Development</i> , 2008 , 22, 894-907	12.6	1780
47	Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. <i>Cancer Research</i> , 2008 , 68, 2329-39	10.1	282
46	Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. <i>Journal of Biological Chemistry</i> , 2008 , 283, 2822-34	5.4	53
45	Transverse Transperineal Repair of a Pessary-induced Mid-rectovaginal Fistula. <i>Journal of Pelvic Medicine & Surgery</i> , 2008 , 14, 199-201		4
44	A special key for unlocking the door to targeted therapies of breast cancer. <i>Scientific World Journal, The</i> , 2008 , 8, 905-8	2.2	
43	The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. <i>Journal of Clinical Investigation</i> , 2008 , 118, 1367-79	15.9	261
42	Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. <i>International Journal of Cancer</i> , 2007 , 121, 1463-72	7.5	197
41	Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. <i>Histopathology</i> , 2007 , 51, 54-62	7.3	41
40	PDGFR-alpha as a potential therapeutic target in uterine sarcomas. <i>Gynecologic Oncology</i> , 2007 , 104, 524-8	4.9	39
39	Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer. <i>Molecular Cancer Research</i> , 2007 , 5, 485-96	6.6	30

38	c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. <i>Cancer Research</i> , 2007 , 67, 1670-9	10.1	217
37	Tyrosine kinase mutations in human cancer. <i>Current Molecular Medicine</i> , 2007 , 7, 77-84	2.5	53
36	Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. <i>Cell Cycle</i> , 2007 , 6, 2585-90	4.7	197
35	Let-7 expression defines two differentiation stages of cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 11400-5	11.5	397
34	Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 66, 1356-65	4	205
33	C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. <i>International Journal of Cancer</i> , 2005 , 113, 678-82	7.5	203
32	Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. <i>Clinical Cancer Research</i> , 2005 , 11, 8538-48	12.9	25
31	Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. <i>Oncogene</i> , 2004 , 23, 9369-80	9.2	146
30	Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia. <i>Gynecologic Oncology</i> , 2004 , 94, 204-7	4.9	10
29	Isolation and characterization of Rac1 pseudogenes (psi1Rac1-psi4Rac1) in the human genome. <i>Gene</i> , 2004 , 341, 189-97	3.8	2
28	Role of beta(3)-endoneixin in the regulation of NF-kappaB-dependent expression of urokinase-type plasminogen activator receptor. <i>Journal of Cell Science</i> , 2002 , 115, 3879-88	5.3	16
27	Ras regulation of urokinase-type plasminogen activator. <i>Methods in Enzymology</i> , 2001 , 333, 105-16	1.7	5
26	Die Physiologie der Zervixreifung. <i>Der Gynakologe</i> , 2001 , 34, 708-714	0.1	6
25	Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2001 , 82, 291-8	4.9	89
24	Transient interaction of activated platelets with endothelial cells induces expression of monocyte-chemoattractant protein-1 via a p38 mitogen-activated protein kinase mediated pathway. Implications for atherogenesis. <i>Cardiovascular Research</i> , 2001 , 49, 189-99	9.9	27
23	Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. <i>Journal of Biological Chemistry</i> , 2001 , 276, 26340-8	5.4	49
22	beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. <i>Molecular and Cellular Biology</i> , 2001 , 21, 2118-32	4.8	45
21	Gastrin induces expression and promoter activity of the vesicular monoamine transporter subtype 2. <i>Endocrinology</i> , 2001 , 142, 3663-72	4.8	32

20	RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene. <i>Methods in Molecular Medicine</i> , 2001 , 39, 299-306		1
19	JNK and p38MAPK are activated during graft reperfusion and not during cold storage in rat liver transplantation. <i>Transplantation Proceedings</i> , 2001 , 33, 931-2	1.1	6
18	Downregulation of a Mitogen-Activated Protein Kinase Signaling Pathway in the Placentas of Women With Preeclampsia. <i>Obstetrics and Gynecology</i> , 2000 , 96, 582-587	4.9	2
17	Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. <i>Oncogene</i> , 2000 , 19, 3013-20	9.2	306
16	The urokinase plasminogen activator system as a novel target for tumour therapy. <i>Fibrinolysis and Proteolysis</i> , 2000 , 14, 114-132		86
15	Downregulation of a mitogen-activated protein kinase signaling pathway in the placentas of women with preeclampsia. <i>Obstetrics and Gynecology</i> , 2000 , 96, 582-7	4.9	17
14	Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. <i>Journal of Biological Chemistry</i> , 1999 , 274, 16377-86	5.4	68
13	UVB increases urokinase-type plasminogen activator receptor (uPAR) expression. <i>Journal of Investigative Dermatology</i> , 1999 , 113, 69-76	4.3	34
12	In vitro modulation of human melanoma cell invasion and proliferation by all-trans-retinoic acid. <i>Melanoma Research</i> , 1998 , 8, 211-9	3.3	62
11	Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. <i>Oncogene</i> , 1997 , 14, 1481-93	9.2	219
10	Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade. <i>Oncogene</i> , 1997 , 14, 2563-73	9.2	61
9	Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. <i>Journal of Cellular Biochemistry</i> , 1996 , 61, 430-43	4.7	42
8	Cytological diagnosis of zosteriform skin metastases in undiagnosed breast carcinoma. <i>British Journal of Dermatology</i> , 1996 , 135, 502-3	4	16
7	Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. <i>Journal of Biological Chemistry</i> , 1996 , 271, 23176-84	5.4	54
6	Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. <i>Journal of Biological Chemistry</i> , 1996 , 271, 10672-80	5.4	291
5	Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. <i>Journal of Biological Chemistry</i> , 1995 , 270, 23007-12	5.4	52
4	Stimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1995 , 1268, 65-72	4.9	22
3	Keratin expression reveals mosaic differentiation in vaginal epithelium. <i>American Journal of Obstetrics and Gynecology</i> , 1993 , 169, 1603-7	6.4	7

2	A streamlined mass spectrometry-based proteomics workflow for large scale FFPE tissue analysis	1
1	The balance between toxic versus nontoxic microRNAs determines platinum sensitivity in ovarian cancer	1